ReviewCancers2020
Rare Germline Genetic Variants and the Risks of Epithelial Ovarian Cancer.
Review in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 36 citations in OpenAlex.
- The Genetic and Molecular Analyses of Rare Candidate GermlineInternational journal of molecular sciences · 2026Article
- Double jeopardy: howFrontiers in cell and developmental biology · 2026Review
- Homologous Recombination Proficiency in High-Grade Serous Epithelial Ovarian Cancer Tumors: The Dark Side of the Moon.Current issues in molecular biology · 2025Review
- Clinicopathological features of Chinese ovarian cancer patients with double heterozygosity for cancer-predisposed genes.BMC cancer · 2025Article
- Rare germline genetic variation in PAX8 transcription factor binding sites and susceptibility to epithelial ovarian cancer.American journal of epidemiology · 2025Article
- Validation of the BOADICEA model for epithelial tubo-ovarian cancer risk prediction in UK Biobank.British journal of cancer · 2024Article
- GermlineJournal of personalized medicine · 2024Article
- Outcomes and the effect of PGT-M in women with hormone-related hereditary tumor syndrome.Frontiers in oncology · 2024Article
- OvaPrint-A Cell-free DNA Methylation Liquid Biopsy for the Risk Assessment of High-grade Serous Ovarian Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Article
- Early-Onset Ovarian Cancer <30 Years: What Do We Know about Its Genetic Predisposition?International journal of molecular sciences · 2023Review
- Germline Mutations in 12 Genes and Risk of Ovarian Cancer in Three Population-Based Cohorts.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2023Article
- UK consensus recommendations for clinical management of cancer risk for women with germline pathogenic variants in cancer predisposition genes:Journal of medical genetics · 2023Article
- Long-term risk of cancer among the first-degree relatives of epithelial ovarian cancer patients: A cohort study with 48 years of follow up.Acta obstetricia et gynecologica Scandinavica · 2023Article
- Molecular Genetic Characteristics ofGenes · 2023Article
- Genetic analyses of DNA repair pathway associated genes implicate new candidate cancer predisposing genes in ancestrally defined ovarian cancer cases.Frontiers in oncology · 2023Article
- Moderate-Risk Genes for Hereditary Ovarian Cancers Involved in the Homologous Recombination Repair Pathway.International journal of molecular sciences · 2022Review
- The Genetic and Molecular Analyses ofCancers · 2022Article
- Case Review: Whole-Exome Sequencing Analyses Identify Carriers of a Known Likely Pathogenic IntronicGenes · 2022Article
- Risk-Reducing Bilateral Salpingo-Oophorectomy for Ovarian Cancer: A Review and Clinical Guide for Hereditary Predisposition Genes.JCO oncology practice · 2022Review
- Rare Hereditary Gynecological Cancer Syndromes.International journal of molecular sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 3 countries.
Funding
Abstract
A family history of ovarian or breast cancer is the strongest risk factor for epithelial ovarian cancer (EOC). Germline deleterious variants in the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.